Atlas Trials

Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy Subjects

Clinical trial NCT05517486 · UNKNOWN

Trial details

NCT number
NCT05517486
Sponsor
Grace Therapeutics Inc.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Postherpetic Neuralgia
Start date
2022-07-26
Primary completion
2022-08-21
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.